New York, NY – For decades, the role of regulatory T (Treg) cells in colorectal cancer has presented a perplexing anomaly in oncology. While these immune cells, known for their "braking" effect on the immune system, are typically associated with worse outcomes in most solid tumors, their presence in colorectal cancer has paradoxically been linked to improved patient survival. This enduring mystery has stymied researchers and complicated therapeutic strategies. Now, a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has finally offered a clear and compelling explanation, revealing that not all Treg cells are created equal, particularly within the complex landscape of colorectal tumors.
Published in the prestigious scientific journal Immunity, the findings illuminate a critical distinction: it’s not merely the quantity of Treg cells, but their specific subtype and function, that dictates their impact on tumor progression. This pivotal discovery holds immense promise for revolutionizing immunotherapy approaches for the vast majority of colorectal cancer patients and may extend its reach to other cancers arising in "barrier tissues" like the skin, stomach, mouth, and throat.
Main Facts: Resolving a Long-Standing Enigma
The central revelation of the MSK study is the identification of two distinct subtypes of Treg cells within colorectal tumors, each playing an opposing role in disease progression. Dr. Alexander Rudensky, PhD, co-senior author of the study and Chair of the Immunology Program at MSK, succinctly articulated this paradigm shift: "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it."
This nuanced understanding fundamentally redefines the relationship between Treg cells and colorectal cancer. The beneficial subtype actively suppresses tumor growth, while the detrimental subtype facilitates it by inhibiting the body’s natural cancer-fighting immune response. Crucially, the study pinpointed specific molecular markers and locations for each subtype, providing actionable targets for future therapeutic development. The findings specifically offer a glimmer of hope for patients with microsatellite stable (MSS) colorectal cancer, a common form of the disease that has historically shown poor responsiveness to existing checkpoint inhibitor immunotherapies.
Chronology: Decades of Dedication Culminate in Breakthrough
This transformative research is the culmination of more than two decades of dedicated scientific inquiry by Dr. Rudensky, a globally recognized authority on regulatory T cells. His foundational work has been instrumental in establishing the critical role of Treg cells in maintaining "immune tolerance," the delicate balance that prevents the immune system from attacking the body’s own healthy tissues, beneficial microbes, and harmless environmental elements. By distinguishing between genuine threats and benign targets, Treg cells act as essential peacekeepers within the immune system.
Over the years, Dr. Rudensky’s laboratory has meticulously unravelled the intricate processes governing Treg cell development, their diverse functional mechanisms, and their profound influence on various disease states, including cancer. This deep, longitudinal understanding of Treg biology provided the essential framework for the current breakthrough.
The present study was spearheaded by a collaborative team of first authors: Dr. Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, PhD, who also served as the study’s other senior author. Their combined expertise in immunology, medical oncology, and computational biology proved indispensable in dissecting the complex data and drawing definitive conclusions. This interdisciplinary approach, a hallmark of cutting-edge cancer research, underscores the collaborative spirit driving innovation at MSK.
Supporting Data: Unpacking the Dual Nature of Treg Cells
Colorectal cancer stands as a significant global health challenge, ranking as the second leading cause of cancer-related death when sexes are combined, according to the American Cancer Society. The MSK researchers strategically focused their investigation on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subtype accounts for a staggering 80% to 85% of all colorectal cancers and, critically, represents a significant unmet need in immunotherapy, as these tumors typically exhibit limited response to current checkpoint inhibitors. This contrasts sharply with cancers characterized by high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd), which have shown remarkable responsiveness to immunotherapy, often allowing patients to avoid aggressive treatments like surgery, chemotherapy, and radiation. Understanding the immune landscape of MSS-CRC was thus a paramount objective.
To meticulously explore the unique characteristics of common colorectal cancers, the research team employed a sophisticated mouse model meticulously developed at MSK. This model faithfully recapitulates the genetic alterations, pathological behavior, and intricate immune microenvironment observed in human colorectal tumors, providing a robust platform for in-depth analysis.
Their detailed investigations led to a seminal discovery: tumor-associated Treg cells segregate into two primary functional groups based on their cytokine production. One group produces interleukin-10 (IL-10), a well-known anti-inflammatory signaling molecule. The other group, notably, does not.
Through a series of carefully designed experiments involving the selective removal of each Treg group in the mouse model, the researchers uncovered profound and contrasting effects on tumor growth:
-
IL-10-positive Treg cells: The Guardians. These cells were found to actively slow tumor growth. Their protective mechanism involves reducing the activity of Th17 cells, another type of immune cell that produces interleukin-17 (IL-17). IL-17 is a cytokine known to act as a growth signal for tumors, promoting their proliferation and survival. By dampening Th17 cell function and subsequently IL-17 levels, IL-10-positive Treg cells effectively put a brake on tumor expansion. Importantly, these beneficial Treg cells were predominantly observed in healthy tissue adjacent to the tumor, suggesting a role in maintaining local immune homeostasis. When these IL-10-positive Treg cells were experimentally depleted, tumors in the mouse models grew more aggressively and rapidly.
-
IL-10-negative Treg cells: The Saboteurs. In stark contrast, the IL-10-negative Treg cells exhibited the opposite effect, actively promoting tumor growth. These cells were found to be potent suppressors of crucial immune defenders, particularly CD8+ T cells. CD8+ T cells, often referred to as "killer T cells," are renowned for their direct cancer-fighting capabilities, recognizing and eliminating malignant cells. By neutralizing the activity of CD8+ T cells, the IL-10-negative Treg cells effectively disarm the immune system, allowing the tumor to evade destruction. This harmful subtype was predominantly localized within the tumor itself, strategically positioned to exert maximum immunosuppressive effect. When these IL-10-negative Treg cells were eliminated from the mouse models, tumors significantly shrank, demonstrating their pro-tumorigenic influence.
To validate these critical preclinical findings, the research team meticulously analyzed tumor samples obtained from human colorectal cancer patients. This translational step confirmed the presence of the same two distinct populations of IL-10-positive and IL-10-negative Treg cells in human disease. Further strengthening their conclusions, the team analyzed clinical outcomes for over 100 colorectal cancer patients. The results were compelling: patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer clinical outcomes. This robust correlation between Treg subtype prevalence and patient prognosis unequivocally underscored the clinical relevance of their discovery.
Dr. Huang emphasized the profound implications of these findings: "This research shows how important these positive cells are. And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
Official Responses: Paving the Way for Selective Immunotherapy
The findings from the MSK study offer a beacon of hope for improving treatment strategies, particularly for the large population of colorectal cancer patients with MSS tumors who currently have limited immunotherapy options. Dr. Rudensky, also a Howard Hughes Medical Institute Investigator, highlighted a promising therapeutic avenue identified by the research: targeting CCR8.
The study revealed that the harmful IL-10-negative Treg cells, which are primarily located within the tumor microenvironment and actively suppress the immune response, express exceptionally high levels of a protein known as CCR8. This cell-surface receptor acts as a distinctive marker for this detrimental Treg subtype.
This observation aligns perfectly with earlier pioneering work from Dr. Rudensky’s laboratory, led by breast cancer surgeon Dr. George Plitas, MD. Their previous research demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That prior work had already laid the conceptual groundwork for using antibodies to selectively deplete these harmful CCR8-expressing Treg cells. The premise is elegant: by specifically targeting and removing these immunosuppressive cells, the immune system’s intrinsic ability to attack tumors could be unleashed, while leaving the beneficial, non-CCR8-expressing Treg cells intact.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky stated, underscoring the international significance and ongoing development in this area. Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously evaluating this innovative approach both as a standalone therapy and in combination with existing immunotherapies. The new study provides substantial evidence, strengthening the scientific rationale for deploying this CCR8-targeting strategy specifically in colorectal cancer, and potentially extending its application to a broader spectrum of cancers.
Implications: Beyond Colorectal Cancer and the Challenge of Metastasis
The implications of the MSK study extend far beyond colorectal cancer, suggesting a broader paradigm shift in our understanding of Treg cell function across various malignancies. To explore this, the researchers meticulously analyzed a vast dataset of T cells derived from 16 different cancer types. Their analysis revealed striking similarities: the distinct divisions between IL-10-positive and IL-10-negative Treg cells were not unique to colorectal cancer but were also observed in several other cancers affecting critical "barrier tissues," including the skin and the lining of the mouth, throat, and stomach.
Dr. Mitra, who led the extensive data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky, provided insight into this commonality: "What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses." These barrier tissues are continuously challenged by external factors, necessitating a finely tuned immune response that can both defend against pathogens and prevent excessive inflammation or autoimmune reactions. In this context, beneficial Treg cells likely play a crucial role in maintaining tissue integrity and preventing chronic inflammation that can otherwise drive cancer development. This shared immunological environment suggests that therapeutic strategies designed to remove the harmful IL-10-negative Treg cells in colorectal cancer could potentially be effective against these other barrier tissue cancers as well, opening doors for broader clinical application.
However, the study also unveiled a critical nuance concerning metastatic disease, underscoring the complexity of cancer immunology. When the researchers investigated colorectal cancer that had spread to the liver, they observed a markedly different immune pattern compared to primary tumors. In these metastatic lesions, the harmful IL-10-negative Treg cells significantly outnumbered the helpful IL-10-positive cells. Crucially, unlike in primary tumors, the complete removal of all Treg cells in this metastatic context resulted in the shrinkage of the metastatic tumors. This finding highlights a crucial consideration: the immune landscape, and thus the optimal therapeutic strategy, can vary significantly depending on the tissue involved and the stage of the disease. It emphasizes the need for highly personalized treatment approaches that account for the dynamic and evolving nature of the tumor microenvironment as cancer progresses and metastasizes.
In conclusion, the MSK study marks a monumental step forward in our understanding of cancer immunology and opens exciting new avenues for immunotherapy. By resolving the long-standing colorectal cancer paradox and identifying actionable targets like CCR8, researchers at Memorial Sloan Kettering Cancer Center are not only enhancing our ability to treat colorectal cancer but are also providing a blueprint for developing more precise and effective immunotherapies for a wider range of cancers. The journey from fundamental discovery to clinical translation is often long and arduous, but with these insights, the path to better patient outcomes appears clearer and more promising than ever before.
Authors, Funding, and Disclosures
Additional contributing authors to this pivotal study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
The success of this research was significantly bolstered by the integral support of the Integrated Genomics Operation and the Single Cell Research Initiative at MSK.
Generous funding for this study was provided by critical grants from the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky disclosed his affiliations, serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and holds editorial roles with the Journal of Experimental Medicine and Immunity.
It is also important to note that Dr. Rudensky and Dr. Plitas are recognized inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies targeting CCR8. These disclosures underscore the potential translational impact and commercial interest in the groundbreaking discoveries made by the research team.
About the Author
